Search Results "#Burosumab"

Blogs

arrow_forward View More Results
X-Linked Hypophosphatemia XLH Treatment Market: How Is Burosumab Becoming the Fastest-Growing Targeted Therapy Replacing Conventional Management?
Posted by Surbhi 2 hours, 26 minutes ago   public
Burosumab for X-linked hypophosphatemia — the anti-FGF23 monoclonal antibody subcutaneous injection for phosphate-wasting rickets and osteomalacia representing the fastest-growing targeted therap...
Osteomalacia Treatment Market: How Is Targeted Vitamin D Supplementation with Active Metabolites Becoming the Fastest-Growing Therapeutic Approach?
Posted by Surbhi on July 23 2026 at 06:10 PM   public
Targeted vitamin D supplementation with active metabolites in osteomalacia — the precision dosing of cholecalciferol, ergocalciferol, and calcitriol (1,25-dihydroxyvitamin D) based on 25(OH)D lev...
arrow_forward